AIM ImmunoTech Inc. (AIM)
NYSE American
Key stats Fiscal year 2025
Income statement
- Revenue
- 88,000 -48.2%
- Net income
- -13,958,000
- Operating income
- -11,664,000
- Earnings per share
- -8.62
- R&D expense
- 3,924,000
Growth and profitability
- Operating margin
- -13,254.55
- Net margin
- -15,861.36
- Return on assets
- -241.40
Balance sheet
- Total assets
- 5,782,000
- Total liabilities
- 15,565,000
- Shareholders' equity
- -9,783,000
- Cash and equivalents
- 2,985,000
- Debt
- 4,476,000
- Net debt
- 1,491,000
- Current ratio
- 0.53
Cash flow and ratios
- Operating cash flow
- -10,957,000
Shareholder returns
- Shares outstanding
- 39,919,844
Company information
- Headquarters
- Ocala, FL
- Exchange
- NYSE American
- Fiscal year end
- 12-31
- Industry (SEC)
- Biological Products, (no Diagnostic Substances)
Fiscal year end: · Source: SEC EDGAR
AIM ImmunoTech Inc. trades on NYSE American under the ticker symbol AIM. This page brings together its price chart, company profile, key financial figures and technical indicators.